Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant batroxobin for hemostasis in posterior cervical and lumbar spine surgery
ChiCTR2200065989Phase 3Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant batroxobin in Cervical discopathy (CDDD) and lumbar intervertebral disc degenerative disease (LDDD) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoints: Intraoperative blood loss and Venous thromboembolism. Started Jul 2021; status: recruiting.
02
Drugs
recombinant batroxobin
03
Conditions
Cervical discopathy (CDDD)lumbar intervertebral disc degenerative disease (LDDD)
Beyond the preview
Go deeper on ChiCTR2200065989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065989.